Generics BulletinANI Pharmaceuticals has welcomed record Generics revenues of $98.7m in the first quarter, an increase of 40.5% year-over-year, driven by the launch earlier this year of the first US generic version
Generics BulletinANI Pharmaceuticals forecasts a roughly 25% growth in revenue for 2024, on the back of strong performance of its generic and rare disease businesses. As of now, the company’s total net revenue guidanc
Generics BulletinANI Pharmaceuticals has championed its “superior R&D capabilities” after launching the first US generic version of Takeda’s Motegrity (prucalopride) tablets. The US firm’s launch – via its Noviti
Generics BulletinANI Pharmaceuticals has again beat some analyst estimates, receiving praise at a transformative point for the company following its acquisition of Alimera Sciences earlier in autumn. Notably, ANI mana